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Noninvasive diagnosis, whether by sampling body fluids, body scans, or other technique, has the potential to simplify early cancer
detection. A classic example is Pap smear screening, which has helped to reduce cervical cancer 75% over the last 50 years. No test
is error-free; the real concern is suﬃcient accuracy combined with ease of use. This paper will discuss methods that measure gene
expression or epigenetic markers in oral cells or saliva to diagnose oral and pharyngeal cancers, without requiring surgical biopsy.
Evidence for lung and other distal cancer detection is also reviewed.

1. Introduction
This year half a million people will be diagnosed with oral
squamous cell carcinoma (OSCC) or oropharyngeal cancer,
and about one quarter of that number will die from the
disease, often disfigured from treatment. Cure rates have
improved only slightly over the decades. Paradoxically, while
early curable lesions are visible in the mouth, they are seldom
diagnosed. Because oral and oropharyngeal cancers are often
asymptomatic until the final stages, improved screening to
detect cancerous lesions in the oral cavity is a key component
to reducing this cancer [1]. Detection of suspicious oral
lesions by a general dentist includes a visual inspection of
the oral mucosa and visible throat. The clinician looks for
either nonhomogenous or verrucous surfaces, of unknown
cause, whitish or reddish in color. The examination of the
oral cavity can be aided by toluidine blue vital staining,
because the dye is retained in cells with malignant changes,
or by the use of a fluorescent light source as premalignant
and malignant lesions may diﬀer from normal mucosa in
their production of fluorescence [1]. On the detection of
a suspicious lesion (of duration over 2 weeks), the patient
may be advised to make an appointment with an oral

surgeon so the lesion can be biopsied. The histopathological
examination of a stained tissue section by a pathologist is
the gold standard for diagnosis of oral neoplasia. A diagnosis
is made based on changes in cell and nuclear size and
mucosal architecture. Problems with this procedure include
the diﬃculty for all but the most experienced practitioners
to know which part of a heterogeneous lesion should be
sampled, the need for multiple biopsies, the preference of
only some dentists and physicians to perform oral biopsies,
the refusal of some patients to submit to oral biopsies,
and the subjective nature of the pathological analysis. The
invasive nature and skill required to perform the procedure
limit its usefulness as a part of oral cancer screening.
The procedure of using a cytology brush to harvest
mucosal cells from suspicious lesions to detect OSCC and
oropharyngeal cancer was first attempted many years ago as
reviewed earlier [2]. These cells can be used for cytological
evaluation after staining. This methodology, oﬀered by one
company in particular, OralCDx, has been promoted over
the last 12 years as a substitute for tissue pathology [3, 4].
More ambitious approaches use cells from the oral cavity or
throat obtained with a brush or oral rinse as a source of DNA
or RNA that can be used to determine mutations [5, 6] or
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changes in gene expression linked to cancer. Finally, saliva
itself can be analyzed to detect RNA that is associated with
not only head and neck squamous cell carcinoma (HNSCC)
but also systemic cancers. All these approaches oﬀer the
admirable goal of eliminating the need for oral biopsy as a
methodology of OSCC detection.

2. RNA from Brush Oral Cytology
Until 2004 it was largely thought that RNA harvested from
the oral mucosa using a cytology brush would be so severely
degraded as to disallow the identification of specific mRNAs
[7]. Early pilot studies demonstrated that the isolation of
RNA from brush oral cytology was possible and that mRNA
could be detected using RT-PCR or microarray analysis, but
it was not clear how reliable the method was and what
was being measured [8, 9]. Remarkably, in their pioneering
human study Spivack et al. saw a qualitative correlation
of detectable expression of a number of mRNAs in laser
microdissected lung tissue and brush cytology cells from
the same patients [9]. However, large interpatient variability
in mRNA quantitation was seen (up to 10,000 fold), and
the source of this variation was not explored. In a pilot
study, increased levels of the L5gamma2 mRNA in RNA from
brush cytology were found in human oral carcinoma versus
normal tissue, though this study lacked statistical analysis
of the data [10]. A source of variation in these studies
may be methods of RNA preparation and analysis and
statistical data evaluation. Finally, pilot studies demonstrated
increases in KRT17 mRNA and the splice variant ATP6V1C
mRNA in RNA from brush cytology of OSCC [11, 12].
Studies done comparing RNA from brush cytology of benign
mucosa of smokers and nonsmokers have shown diﬀerential
expression of genes by global gene expression analysis that
were verified using RT-PCR, though the RNA was not 100%
intact [13, 14]. It has been our finding that careful selection
of primer target size allows reproducible measurement of
specific mRNAs in RNA from brush cytology [15]. Over the
last 4 years we have shown that not only is the RNA of high
enough quality to allow the measurement of specific mRNAs
but also that samples taken over consecutive weeks from
OSCC in hamster showed consistent levels of specific mRNAs
[15]. Reproducibility was further verified in healthy mucosa
in human subjects [16].
The diﬃculty in extracting totally intact mRNA from
brush oral cytology is thought to be due to the high level of
ribonuclease in saliva present during cell collection, storage,
and processing, which results in diﬀerences in levels of
specific mRNAs [17, 18]. Another important contribution to
the RNA quality may be the dead and dying cells that make
up the squamous epithelium. In fact a case could be made
that brush cytology samples of any squamous epithelium,
such as skin, cervix, or oral and pharyngeal tissue, are
going to include partially degraded RNA. Despite this, RNA
from brush cytology has shown changes in gene expression
supported by work from diﬀerent laboratories when RT-PCR
is used with suitable mRNA controls and consistent primer
design [15, 16, 19, 20].
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There is a large legacy of over 20 earlier studies on global
gene expression changes measured in surgically obtained
tissues for HNSCC, mainly of the oral cavity, oropharynx,
hypopharynx, and larynx [21–25]. These supply a list of
over 100 genes that show expression changes correlated to
HNSCC that can be tested using RT-PCR with RNA from
brush oral cytology of suspect malignant lesions. RNA from
brush oral cytology of the oral mucosa represents almost
exclusively cells of a single type in contrast to tissue from
surgical samples which include variable amounts of stromal
tissue. Despite the claims of some brush producers, the
brush collects cells from at best the top 2/3 of the mucosal
in normal tissue, typically 100% epithelial cells [26]. As is
now well understood, analysis of homogeneous cells allows
much more sensitive detection of gene expression changes of
that cell type [15, 27]. Brush cytology provides nearly pure
epithelial cells without the need for tissue microdissection.
Work from our laboratory exploited the list of OSCC marker
genes in surgically obtained head and neck tumor tissue [21–
25]. Twenty-one mRNAs from this list were quantified in
RNA from brush cytology samples of OSCC associated with
tobacco usage and benign oral lesions. Six mRNAs showed
diﬀerential expression, and an OSCC classifier was developed
based on the level of 5 mRNAs, with 4 from the list (data
not shown). These data and results from other laboratories,
while requiring further validation, lend support to the idea
that a well-designed screen of RNA from brush cytology has
the potential to aid in OSCC screening [11, 12, 15, 16].

3. RNA from Cell-Free Saliva
While basic research scientists catalogue gene expression,
identifying genes actively synthesizing mRNAs that are
translated into protein, the clinician is more interested in
mRNAs as markers whose levels correlate with disease. For
some years eﬀorts have been made to correlate the presence
of oral cancer with changes in specific RNAs in saliva [28,
29]. From the start, this approach has been championed
by one group that has worked to perform the diﬃcult task
of cataloging mRNA fragments in cell-free saliva. With the
rationale that the best screening method uses the easiest
sample collection, the Wong group has kept the methodology
simple. No eﬀort is made to induce salivation; patients are
only asked to refrain from eating one hour prior to sample
acquisition and samples are taken at a uniform time of day
and placed in a RNA preservative.
The original finding that RNA could be detected in saliva
was unexpected despite the fact that multiple RNA forms
had been detected in plasma [30]. It was originally thought
that no RNA could survive extracellularly due to the high
level of ribonuclease in saliva [17, 18, 31]. Although one
report showed RNA is undetectable in saliva, there is ample
evidence that there is extracellular RNA in saliva at very
low levels [32–34]. The source was originally thought to
be nearby lysed oral or pharyngeal tumor cells. However,
measured changes in salivary RNAs with systemic disease,
such as mammary and pancreatic cancer, led to the idea that
RNA in saliva comes from plasma prior to its secretion by the
salivary glands [35, 36]. Now it is understood that while RNA
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can be found in plasma or saliva, perhaps bound to proteins,
another source is exosomes [37–39]. These small membranebound vesicles can be produced in many cells and are
thought to be part of a not well-understood exchange system
for mRNA, miRNA, protein, and other macromolecules.
Because exosomes are thought to freely travel in the blood
and possibly exchange in other body fluids such as saliva,
it would then be understandable how diseases at distal sites
can contribute to saliva RNA populations. Also, perhaps with
the acceptance that most saliva mRNAs are likely to be in
exosomes, appropriate refinements in RNA purification may
improve quality and yield of saliva RNA preparations [39].
The evidence for saliva-based RNA as a classifier for
OSCC, and that changes in saliva RNA levels are linked to a
variety of diseases, is almost exclusively from one laboratory.
On the subject of OSCC there is a published study from
another group that showed RT-PCR detectable MMP1 in
saliva in 20% of OSCC patients but not in any healthy controls [40]. In this study RNA from centrifuged saliva pellets
was examined, not cell-free saliva, and a set of 3 mRNAs
served as controls. The original publication from the Wong
group demonstrating mRNAs with increased concentration
in saliva associated with OSCC was based on 32 patients with
early stage OSCC and 32 healthy, age and smoking history
matched controls [29]. Quality control was the detectability
of housekeeping RNAs by RT-PCR. Microarray analysis
initially showed 17 mRNAs were overrepresented in cell-free
saliva of OSCC patients while no genes were downregulated.
This may suggest an increased overall level of RNA in saliva
of OSCC patients. Remarkably, after focusing on the genes
known to be associated with cancer, 7 out of 9 showed
increased levels in saliva using RT-PCR; these were IL8, IL1B,
DUSP1, HA3, OAZ1, S100P, and SAT. Li et al. then created
a classifier for OSCC based on levels of these 7 RNAs in
saliva, reporting a sensitivity of 0.91 and a specificity of 0.91
using the same training set [29]. A study from the same
group in 2010 focused on a Serbian population diﬀering in
race and including all OSCC tumor stages. In that study,
6 out of the 7 original mRNAs were tested using nested
RT-PCR, and all values were normalized to control RNAs
from 3 housekeeping genes, not to saliva volume as in the
first study [41]. While the study did validate the increase
in levels of 4 out of 6 RNAs tested in this population of
patients with OSCC, it by no means validated their value
as a classifier for OSCC as substantial changes were made
to the original classifier after testing multiple alternatives. It
will be important to validate this new classifier of 4 saliva
RNAs and 3 saliva proteins, without modification, in a study
of independent subjects.
The discovery that extracellular RNA in saliva is protected in exosomes added great strength to the idea that
RNA in cell-free saliva could be used to diagnose systemic
disease. The Wong group has done multiple studies linking
changes in saliva RNA to systemic disease including ovarian
and pancreatic cancer [35, 36]. While the two studies named
do show diﬀerential expression of certain marker RNAs in
saliva for both diseases using two sets of patient samples,
they did not maintain separate test and validation patient
sample sets when developing the classifier predictive of the
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disease under study. For that reason, it is likely that the high
level of sensitivity and specificity for disease identification by
measuring the mRNAs they recommend will likely decrease
when a true independent set of patient saliva samples is
examined and that further refinement of the classifier will
be necessary with the measurement of additional or diﬀerent
RNAs. The initial observation of relatively intact RNA in
the extracellular saliva by the Wong group was a seminal
finding. However, validation for all the disease classifiers with
an independent set of subjects is needed before the use of
salivary RNA as a screen for disease can be fully evaluated
[37–39].

4. Epigenetic Changes in
DNA from Cells in Saliva
Alterations in gene promoter methylation provide a method
to detect OSCC by DNA analysis. Hypermethylation of CpG
islands in the promoter regions of many tumor suppressor
genes has been linked to the loss of expression of these
genes that occurs with the multiple tumor types that make
up the family of HNSCCs. In recent years, this method of
tumor cell analysis has overshadowed mutational analysis
of the HNSCC or OSCC genome as having promise to
identify these diseases. To perform methylation analysis,
DNA isolated from tumor tissue is exposed to bisulfite to
convert cytosines not methylated at the 5 position to uracil,
followed by hybridization of oligonucleotide primers to the
altered sequence and detection using PCR. This produces
a quantitative measure of methylation at specific CpG sites
after normalization to a housekeeping gene promoter site
known not to show diﬀerential methylation. While these
analyses have been done with surgically obtained oral tissue,
they can also be done with exfoliated cells from saliva or an
oral rinse with or without a previous brushing to dislodge
cells [42, 43]. This greatly simplifies cell acquisition, especially from unseen pharyngeal lesions, though it dilutes the
numbers of cells that come directly from the lesion. Possibly
because tumors may tend to shed cells at high rates and field
cancerization can cause changes in gene expression in wide
areas of tissue around a tumor, the method seems to work.
Usage of exfoliated cells and not surgically acquired tumor
tissue showed only a slight decrease in sensitivity to promoter
methylation detection and then only for some genes [44, 45].
A major stumbling block to DNA methylation studies in
the past was the relatively large amount of material needed to
perform the analysis and the lack of a true high throughput
approach to catalog diﬀerential promoter methylation. While
DNA microarray hybridization analysis allows the measurement of the levels of thousands of RNAs in one experiment,
methylation studies of CpG islands in promoters have, until
recently, been done one gene at a time, typically on genes first
identified as hypermethylated in HNSCC cells lines. As one
might expect hyper- and hypo-CpG methylation patterns
that occur in HNSCC cell lines can be markedly diﬀerent
than those seen in tumor tissue [46]. Of the published
records, of about 50 prospective genes tested as methylation
markers for HNSCC or OSCC in saliva, only a few have
shown utility to accurately identify these diseases [44].
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Nevertheless, this approach has provided studies linking
hypermethylation of certain genes in cells found in oral
rinses to not only HNSCC but also moderate-to-severe
dysplasias based on EDNRB promoter methylation and to
verrucous HNSCC relapse prediction based on methylation
status of specific promoter sites in a panel of 5 genes [45, 47].
In the last few years, high throughput DNA methylation
assays have become available that oﬀer multiplexed systems
for determination of CpG methylation status at thousands
of sites at once [44, 48]. As an example, recent work using
this approach with oral tissue from 4 OSCCs, 4 leukoplakia
patients, and 4 healthy controls detected 301 hypermethylated and 62 hypomethylated genes promoter sites [44]. That
research focused on 8 genes shown to be underexpressed in
HNSCC and also hypermethylated in at least some tumor
types in earlier studies. Four of these were used to identify
SCC among a validation set of 55 HNSCC and 37 normal
surgically obtained tissue samples, with 94% sensitivity and
97% specificity. Accuracy dropped greatly when used on
DNA harvested from oral rinses of patients with HNSCC and
controls. The loss of accuracy may be due to the use of saliva
cells while the classifier was developed with tumor tissue. As
noted, certain genes show poor correlation in methylation
status between tissue and exfoliated cells. This suggests that,
if possible, exfoliated cells from patients should be used
directly for the multiplexed analysis of gene methylation
status with HNSCC though the amounts of DNA are more
limited. With the ability to rapidly screen many methylation
sites, DNA hypermethylation analysis of oral rinse cells
may allow the rapid identification of genes ideal for OSCC
and oropharyngeal cancer classification. It also must be
recognized that OSCC and oropharyngeal cancer can be
diﬀerent cancers with diﬀerent etiologies, gene expression,
and mutation patterns and that attempts to provide a single
classifier for all the forms may be diﬃcult or impossible
[49, 50].
Methylation-based HNSCC diagnosis using saliva cells
holds much promise. DNA is much more stable than RNA,
and it is assumed that even in exfoliated cells the loss
of methylation and DNA degradation occur at low rates
and are not a factor, though that will need to be verified.
As has been noted, standardization of sample acquisition
and DNA purification will be necessary [48]. It will be
interesting to see if saliva DNA methylation analysis will
show suﬃcient sensitivity to detect oral premalignancy or
if it will be necessary to use a cytology brush to increase
the number of cells from the lesion. It will be crucial to
show that the methodology not only diﬀerentiates HNSCC
from healthy mucosa but also from benign pathology, such
as reactive inflammation, to increase specificity in the clinic.
Examination of oral cells also may prove useful in the
analysis of some systemic diseases. Methylation of gene
promoters of cells in saliva or obtained with a brush from
the oral mucosa has been linked to cigarette smoke-induced
changes in the lungs [51–53]. It has been suggested as an
alternative to lung biopsy to noninvasively size up changes
in the lungs using saliva DNA methylation analysis with
the goal of providing guidance on lung cancer susceptibility.
Furthermore, the characterization of cells in sputum from
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the respiratory system showed changes in DNA promoter
methylation associated with lung cancer [54]. It is speculated
that traces of DNA in respired air can also be scanned for the
presence of methylation of specific sites of the DNA to track
lung cancer, though this approach is in its infancy [55].

5. Discussion
RNA from brush cytology and DNA from oral rinses
come almost exclusively from epithelial cells of oral and
adjoining tissue mucosa. As stated earlier homogeneous
samples oﬀer more sensitive detection of RNA population
changes in the cells of interest. It may also eliminate much
of the variability between studies that use surgical samples
harvested in diﬀerent ways and thus containing variable
amounts of stroma, a problem that has plagued betweenlaboratory comparisons of gene expression-based classifiers.
While studies using oral cells to measure RNA, or DNA
methylation, have taken advantage of genes identified in
earlier studies of surgically obtained tissue, new genes better
suited to OSCC and HNSCC identification may also come to
light, given the pure cell population used.
Analysis of RNA from brush cytology and methylated
DNA from oral rinses shows great promise to oﬀer screening
for oral disease. There is a need for more evidence that both
methods work with external validation sets, though less so
for analysis of DNA from oral rinses where more studies
have been done. While studies on RNA from brush cytology
has compared samples from malignant versus benign lesions,
most research on DNA methylation in oral rinses have
compared malignant versus healthy tissue. Thus there is
a need to establish if the latter method can diﬀerentiate
malignant versus benign disease.
RNA from cell-free saliva may allow detection of oral
and systemic disease based on changes in RNA in the
saliva. This is thought to be due to the presence of RNA
released throughout the body and carried to the oral cavity
via the blood. The high number of cell types thought to
be contributing to the extracellular saliva RNA population
makes it diﬃcult to suggest there will be RNA signatures
suﬃciently specific to systemic diseases to allow accurate
detection of a large number of these diseases. However,
the possibility of using this approach to detect oral and
oropharyngeal disease where the diseased cells should be a
dominant RNA source is promising for this method whose
great virtue may be the simplicity of sample collection.
Interestingly, recent analyses from several groups suggest that
the analysis of miRNA in both unfractionated and cell-free
saliva may have potential to provide a classifier for OSCC
[56–58].
A major question is how will any of the three methodologies be used in the clinic if they do prove to add value
to diagnosis? There is great commercial interest in the
development and manufacture of portable instrumentation
for automated isolation of DNA and RNA from samples
outside the laboratory, performance of cDNA synthesis, or
bisulfite reaction, followed by PCR allowing quantification
of the sequences of interest. Direct hybridization detection
of targets will in time simplify the methodology. While these
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machines are chiefly designed for use with blood, they are
adaptable to saliva analysis and should provide point-of-care
rapid diagnosis of oral disease in the dental or medical clinic,
eliminating the need for patient referral for this in just a few
years.

6. Conclusion
Noninvasive methods using gene expression analysis to
detect early oral malignancy will likely be used in the clinic
to provide point-of-care detection in five years time and for
definitive diagnosis sometime after that. At this point, the
analysis of DNA methylation has the most promise to be the
method of choice. Unlike RNA from brush cytology, DNA
methylation has had a large number of resources directed
toward it, and, diﬀering from analysis of extracellular RNA
in saliva, it has shown utility by several research groups.
Recent findings provide encouragement that the days of
missing early and curable cancerous lesions of the mouth and
pharynx for lack of a simply applied screen are coming to a
close.
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